Guggenheim Initiates Coverage On Signify Health with Buy Rating, Announces Price Target of $36
Guggenheim analyst Sandy Draper initiates coverage on Signify Health (NYSE:SGFY) with a Buy rating and announces Price Target of $36.
Expert Ratings For Signify Health
Analysts have provided the following ratings for Signify Health (NYSE:SGFY) within the last quarter:
Goldman Sachs Maintains Buy on Signify Health, Raises Price Target to $22
Goldman Sachs analyst Cindy Motz maintains Signify Health (NYSE:SGFY) with a Buy and raises the price target from $20 to $22.
Piper Sandler Maintains Overweight on Signify Health, Lowers Price Target to $27
Piper Sandler analyst Sean Wieland maintains Signify Health (NYSE:SGFY) with a Overweight and lowers the price target from $34 to $27.
Earnings Scheduled For March 2, 2022
Companies Reporting Before The Bell
• SIGNA Sports United (NYSE:SSU) is expected to report quarterly loss at $0.04 per share on revenue of $283.61 million.
Earnings Outlook For Signify Health
Signify Health (NYSE:SGFY) is set to give its latest quarterly earnings report on Wednesday, 2022-03-02. Here's what investors need to know before the announcement.
Analysts estimate that Signify Health will report an earnings per share (EPS) of $0.03.
Cathie Wood’s ARK Invest Posts Fund Purchases For Monday, Nov. 15, 2021: NTLA, TWOU, VCYT, BEAM, MTLS, PRLB, TSP, ACHR, VLD, SPLK, DIS, BFLY, SGFY, ONEM, ALLO, VERV, QSI, HOOD, DKNG, TWLO, TOST, PAG, GRMN, DDD, MKFG
Intellia Therapeutics (NTLA)
2U (TWOU)
Veracyte (VCYT)
Beam Therapeutics (BEAM)
Materialise (MTLS)
Proto Labs (PRLB)
TuSimple Holdings (TSP)
Archer Aviation (ACHR)
Velo3d (VLD)
Splunk (SPLK)
The Walt Disney
76 Biggest Movers From Yesterday
Gainers
Expensify, Inc. (NASDAQ: EXFY) jumped 52.1% to settle at $41.06 on Wednesday after the company priced its IPO at $27 per share.